Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin

Callmann, Cassandra E.; LeGuyader, Clare L. M.; Burton, Spencer T.; Thompson, Matthew P.; Hennis, Robert; Barback, Christopher V.; Henriksen, Niel M.; Chan, Warren C. W.; Jaremko, Matt J.; Yang, Jun; Garcia, Arnold; Burkart, Michael D.; Gilson, Michael K.; Momper, Jeremiah D.; Bertin, Paul; Gianneschi, Nathan C.

doi:10.1021/jacs.9b04272

Cited by 67 publications

(51 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the tumor size reached 200–250 mm 3 , the mice were intravenously injected with DiR-labelled liposomes (DiR-Lipo) or free DiR. 22 At predetermined time intervals (1, 2, 4, 8, 24 and 48 h), the mice were anaesthetized with isoflurane and photographed. At 24 h and 48 h post-injection, the mice were sacrificed, and the main organs and tumors were collected for imaging.…”

Section: Methodsmentioning

confidence: 99%

Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity

Gao¹,

Zhang²,

He³

et al. 2021

IJN

View full text Add to dashboard Cite

Background: BF211, a derivative of bufalin (BF), shows significantly improved solubility and potent antitumor efficiency compared to BF. Unfortunately, the unwanted toxicity such as cardiotoxicity caused by unspecific distribution has hindered its clinical use. Methods: PEGylated BF211 liposomes (BF211@Lipo) were designed and optimizely prepared based on the pre-prescription research. In vitro and in vivo cardiotoxicity was evaluated. In vivo pharmacokinetics and biodistribution of BF211@Lipo were investigated. In vivo antitumor activity and toxicity were evaluated in HepG2 cell xenograft models. The rapid-release triggered by Poloxamer 188 (P188) was assessed in vitro and in vivo. Results: The optimized BF211@Lipo displayed a spherical morphology with a size of (164.6 ± 10.3) nm and a high encapsulation efficiency of (93.24 ± 2.15) %. The in vivo concentration-time curves of BF211 loaded in liposomes showed a prolonged half-life in plasma and increased tumor accumulation. No obvious abnormality in electrocardiograms was observed in guinea pigs even at 9 mg/kg. Moreover, to improve the efficient release of BF211@Lipo, a surfactant-assisted rapid-release strategy was developed, and the releasepromoting mechanism was revealed by the fluorescence resonance energy transfer (FRET) and fluorescence nanoparticle tracking analysis (fl-NTA) technology. Sequential injection of BF211@Lipo and P188 could ignite the "cold" liposomes locally in tumor regions, facilitating the burst release of BF211 and enhancing the therapeutic index. Conclusion: Our progressive efforts that begin with preparation technology and dosage regimen enable BF211 to like a drug, providing a promising nano platform to deliver the cardiac glycosides and alleviate the side effects by decreasing unspecific biodistribution.

show abstract

Section: Methodsmentioning

confidence: 99%

Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity

Gao¹,

Zhang²,

He³

et al. 2021

IJN

View full text Add to dashboard Cite

show abstract

“…[ 236 ] The continued efforts to improve the PTX‐protein formulation lead to the discovery of long‐chain fatty acids (LCFAs)‐PTX prodrug that can readily formed noncovalent complex with HAS, kept LCFAs binding pose unchanged, differed in pharmacokinetics, shown higher maximum tolerated doses (Figure 15E ) and increased efficacy in vivo in multiple cancer models, compared to clinical formulations Abraxane and Cremophor EL‐formulated PTX. [ 237 ]…”

Section: Biomacromolecule‐drug Conjugatesmentioning

confidence: 99%

Nanoparticulation of Prodrug into Medicines for Cancer Therapy

et al. 2021

View full text Add to dashboard Cite

This article provides a broad spectrum about the nanoprodrug fabrication advances co-driven by prodrug and nanotechnology development to potentiate cancer treatment. The nanoprodrug inherits the features of both prodrug concept and nanomedicine know-how, attempts to solve underexploited challenge in cancer treatment cooperatively. Prodrugs can release bioactive drugs on-demand at specific sites to reduce systemic toxicity, this is done by using the special properties of the tumor microenvironment, such as pH value, glutathione concentration, and specific overexpressed enzymes; or by using exogenous stimulation, such as light, heat, and ultrasound. The nanotechnology, manipulating the matter within nanoscale, has high relevance to certain biological conditions, and has been widely utilized in cancer therapy. Together, the marriage of prodrug strategy which shield the side effects of parent drug and nanotechnology with pinpoint delivery capability has conceived highly camouflaged Trojan horse to maneuver cancerous threats.

show abstract

“…It should also be noted that proteins often contain various functional structure elements created by the specific arrangement of protein chain fragments. A typical example is human serum albumin used to complex drugs and other bioactive compounds [ 129 , 130 , 131 ]. Special attention attracted derivatives of relatively short polypeptides, particularly block copolymers containing blocks of poly(ethylene oxide) and poly(aspartic acid); carboxyl groups of poly(aspartic acid) could easily be modified and/or used for drug conjugation.…”

Section: Polymers For Preparation Of Drug Delivery Carriersmentioning

confidence: 99%

Functionalized Particles Designed for Targeted Delivery

et al. 2021

View full text Add to dashboard Cite

Pure bioactive compounds alone can only be exceptionally administered in medical treatment. Usually, drugs are produced as various forms of active compounds and auxiliary substances, combinations assuring the desired healing functions. One of the important drug forms is represented by a combination of active substances and particle-shaped polymer in the nano- or micrometer size range. The review describes recent progress in this field balanced with basic information. After a brief introduction, the paper presents a concise overview of polymers used as components of nano- and microparticle drug carriers. Thereafter, progress in direct synthesis of polymer particles with functional groups is discussed. A section is devoted to formation of particles by self-assembly of homo- and copolymer-bearing functional groups. Special attention is focused on modification of the primary functional groups introduced during particle preparation, including introduction of ligands promoting anchorage of particles onto the chosen living cell types by interactions with specific receptors present in cell membranes. Particular attention is focused on progress in methods suitable for preparation of particles loaded with bioactive substances. The review ends with a brief discussion of the still not answered questions and unsolved problems.

show abstract

Antitumor Activity of 1,18-Octadecanedioic Acid-Paclitaxel Complexed with Human Serum Albumin

Cited by 67 publications

References 44 publications

Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity

Surfactant Assisted Rapid-Release Liposomal Strategies Enhance the Antitumor Efficiency of Bufalin Derivative and Reduce Cardiotoxicity

Nanoparticulation of Prodrug into Medicines for Cancer Therapy

Functionalized Particles Designed for Targeted Delivery

Contact Info

Product

Resources

About